Role of the XRCC5/XRCC6 dimer in carcinogenesis and pharmacogenomics

Pharmacogenomics

Volumn 12, Issue 4, 2011, Pages 515-534

  Bau, Da Tian ^a   Tsai, Chia Wen ^a   Wu, Cheng Nan ^a,b  

^a CHINA MEDICAL UNIVERSITY HOSPITAL   (Taiwan)

^b CENTRAL TAIWAN UNIVERSITY OF SCIENCE AND TECHNOLOGY   (Taiwan)

Author keywords

cancer; carcinogenesis; polymorphism; XRCC5; XRCC6

Indexed keywords

BORTEZOMIB; DIMER; IRINOTECAN; LENALIDOMIDE; MERCAPTOPURINE; NUCLEAR PROTEIN; NUCLEIC ACID BINDING PROTEIN; TAMOXIFEN; THALIDOMIDE; UNCLASSIFIED DRUG; XRCC5 PROTEIN; XRCC6 PROTEIN;

BLADDER CANCER; BREAST CANCER; CANCER INCIDENCE; CANCER SUSCEPTIBILITY; CARCINOGENESIS; COLORECTAL CANCER; DERMATITIS; DNA REPAIR; DRUG EFFICACY; DRUG RESPONSE; DYSPHAGIA; ESOPHAGUS CANCER; GENETIC ASSOCIATION; GENETIC RISK; GENETIC SUSCEPTIBILITY; GENOTYPE; GLIOMA; HEAD AND NECK CANCER; HUMAN; INTENSITY MODULATED RADIATION THERAPY; ION THERAPY; KIDNEY CARCINOMA; LUNG CANCER; MENINGIOMA; MOUTH CANCER; MUCOSA INFLAMMATION; MULTIPLE CANCER; MULTIPLE MYELOMA; NONHUMAN; NUCLEOTIDE SEQUENCE; PHARMACOGENOMICS; PREVALENCE; PROSTATE CANCER; PTERYGIUM; REVIEW; SINGLE NUCLEOTIDE POLYMORPHISM; STOMACH CANCER; THYROID CANCER; VEIN THROMBOSIS;

ANTICARCINOGENIC AGENTS; ANTIGENS, NUCLEAR; CELL TRANSFORMATION, NEOPLASTIC; DNA BREAKS, DOUBLE-STRANDED; DNA HELICASES; DNA REPAIR; DNA-BINDING PROTEINS; DRUG RESISTANCE, NEOPLASM; GENOMIC INSTABILITY; HUMANS; NEOPLASMS; PHARMACOGENETICS; POLYMORPHISM, GENETIC; PROTEIN MULTIMERIZATION;

EID: 79955538371     PISSN: 14622416     EISSN: 17448042     Source Type: Journal    
DOI: 10.2217/pgs.10.209     Document Type: Review

References (137)

1. Hakem R: DNA-damage repair; the good, the bad, and the ugly. EMBO J. 27, 589-605 (2008). (Pubitemid 351273123)
2. Spry M, Scott T, Pierce H, D'Orazio JA: DNA repair pathways and hereditary cancer susceptibility syndromes. Front. Biosci. 12, 4191-4207 (2007).
3. Berwick M, Vineis P: Markers of DNA repair and susceptibility to cancer in humans: an epidemiologic review. J. Natl Cancer Inst. 92, 874-897 (2000). (Pubitemid 30429188)
4. Valerie K, Povirk LF: Regulation and mechanisms of mammalian double-strand break repair. Oncogene 22, 5792-5812 (2003). (Pubitemid 37176701)
5. Pfeiffer P, Goedecke W, Kuhfittig-Kulle S, Obe G: Pathways of DNA double-strand break repair and their impact on the prevention and formation of chromosomal aberrations. Cytogenet. Genome Res. 104, 7-13 (2004). (Pubitemid 38721047)
6. Bassing CH, Chua KF, Sekiguchi J et al.: Increased ionizing radiation sensitivity and genomic instability in the absence of histone H2AX. Proc. Natl Acad. Sci. USA 99, 8173-8178 (2002). (Pubitemid 34651025)
7. Shrivastav M, De Haro LP, Nickoloff JA: Regulation of DNA double-strand break repair pathway choice. Cell Res. 18, 134-147 (2008).
8. Gilley D, Tanaka H, Hande MP et al.: DNA-PKcs is critical for telomere capping. Proc. Natl Acad. Sci. USA 98, 15084-15088 (2001). (Pubitemid 34013973)
9. Goytisolo FA, Samper E, Edmonson S, Taccioli GE, Blasco MA: The absence of the DNA-dependent protein kinase catalytic subunit in mice results in anaphase bridges and in increased telomeric fusions with normal telomere length and G-strand overhang. Mol. Cell. Biol. 21, 3642-3651 (2001). (Pubitemid 32466978)
10. Difilippantonio MJ, Zhu J, Chen HT et al.: DNA repair protein Ku80 suppresses chromosomal aberrations and malignant transformation. Nature 404, 510-514 (2000). (Pubitemid 30186895)
11. Ferguson DO, Alt FW: DNA double strand break repair and chromosomal translocation: lessons from animal models. Oncogene 20, 5572-5579 (2001). (Pubitemid 32928098)
12. Gao Y, Ferguson DO, Xie W et al.: Interplay of p53 and DNA-repair protein XRCC4 in tumorigenesis, genomic stability and development. Nature 404, 897-900 (2000). (Pubitemid 30230344)
13. Zhu C, Mills KD, Ferguson DO et al.: Unrepaired DNA breaks in p53-deficient cells lead to oncogenic gene amplification subsequent to translocations. Cell 109, 811-821 (2002). (Pubitemid 34785997)
14. Lieber MR: The mechanism of human nonhomologous DNA end joining. J. Biol. Chem. 283, 1-5 (2008).
15. Lieber MR, Ma Y, Pannicke U, Schwarz K: Mechanism and regulation of human non-homologous DNA end-joining. Nat. Rev. Mol. Cell. Biol. 4, 712-720 (2003). (Pubitemid 37082186)
16. Gu Y, Seidl KJ, Rathbun GA et al.: Growth retardation and leaky SCID phenotype of Ku70-deficient mice. Immunity 7, 653-665 (1997). (Pubitemid 28156633)
17. Nussenzweig A, Chen C, da Costa Soares V et al.: Requirement for Ku80 in growth and immunoglobulin V(D)J recombination. Nature 382, 551-555 (1996). (Pubitemid 26260699)
18. Walker JR, Corpina RA, Goldberg J: Structure of the Ku heterodimer bound to DNA and its implications for double-strand break repair. Nature 412, 607-614 (2001). (Pubitemid 32772267)
19. Spagnolo L, Rivera-Calzada A, Pearl LH, Llorca O: Three-dimensional structure of the human DNA-PKcs/Ku70/Ku80 complex assembled on DNA and its implications for DNA DSB repair. Mol. Cell 22, 511-519 (2006). (Pubitemid 43740469)
20. Sibanda BL, Chirgadze DY, Blundell TL: Crystal structure of DNA-PKcs reveals a large open-ring cradle comprised of HEAT repeats. Nature 463, 118-121 (2010).
21. Zhang Z, Zhu L, Lin D, Chen F, Chen DJ, Chen Y: The three-dimensional structure of the C-terminal DNA-binding domain of human Ku70. J. Biol. Chem. 276, 38231-38236 (2001).
22. Li L, Moshous D, Zhou Y et al.: A founder mutation in Artemis, an SNM1-like protein, causes SCID in Athabascan-speaking Native Americans. J. Immunol. 168, 6323-6329 (2002). (Pubitemid 34620054)
23. O'Driscoll M, Cerosaletti KM, Girard PM et al.: DNA ligase IV mutations identified in patients exhibiting developmental delay and immunodeficiency. Mol. Cell 8, 1175-1185 (2001). (Pubitemid 34084990)
24. Bau DT, Mau YC, Ding SL, Wu PE, Shen CY: DNA double-strand break repair capacity and risk of breast cancer. Carcinogenesis 28, 1726-1730 (2007).
25. Fu YP, Yu JC, Cheng TC et al.: Breast cancer risk associated with genotypic polymorphism of the nonhomologous end-joining genes: a multigenic study on cancer susceptibility. Cancer Res. 63, 2440-2446 (2003).
26. Hemminki K, Li X: Familial risks in nervous system tumors. Cancer Epidemiol. Biomarkers Prev. 12, 1137-1142 (2003). (Pubitemid 37499435)
27. Liu Y, Zhang H, Zhou K et al.: Tagging SNPs in non-homologous end-joining pathway genes and risk of glioma. Carcinogenesis 28, 1906-1913 (2007). (Pubitemid 47500602)
28. Wang LE, Bondy ML, Shen H et al.: Polymorphisms of DNA repair genes and risk of glioma. Cancer Res. 64, 5560-5563 (2004). (Pubitemid 39095549)
29. Karlsson P, Holmberg E, Lundell M, Mattsson A, Holm LE, Wallgren A: Intracranial tumors after exposure to ionizing radiation during infancy: a pooled analysis of two Swedish cohorts of 28,008 infants with skin hemangioma. Radiat. Res. 150, 357-364 (1998). (Pubitemid 28397356)
30. Preston DL, Ron E, Yonehara S et al.: Tumors of the nervous system and pituitary gland associated with atomic bomb radiation exposure. J. Natl Cancer Inst. 94, 1555-1563 (2002). (Pubitemid 35277279)
31. Sadetzki S, Flint-Richter P, Starinsky S et al.: Genotyping of patients with sporadic and radiation-associated meningiomas. Cancer Epidemiol. Biomarkers Prev. 14, 969-976 (2005). (Pubitemid 40478565)
32. De Stefani E, Boffetta P, Deneo-Pellegrini H et al.: The effect of smoking and drinking in oral and pharyngeal cancers: a case-control study in Uruguay. Cancer Lett. 246, 282-289 (2007). (Pubitemid 44959399)
33. Sturgis EM, Wei Q, Spitz MR: Descriptive epidemiology and risk factors for head and neck cancer. Semin. Oncol. 31, 726-733 (2004). (Pubitemid 39602678)
34. Carles J, Monzo M, Amat M et al.: Single-nucleotide polymorphisms in base excision repair, nucleotide excision repair, and double strand break genes as markers for response to radiotherapy in patients with stage I to II head-and-neck cancer. Int. J. Radiat. Oncol. Biol. Phys. 66, 1022-1030 (2006). (Pubitemid 44633517)
35. Werbrouck J, De Ruyck K, Duprez F et al.: Single-nucleotide polymorphisms in DNA double-strand break repair genes: association with head and neck cancer and interaction with tobacco use and alcohol consumption. Mutat. Res. 656, 74-81 (2008).
36. Werbrouck J, De Ruyck K, Duprez F et al.: Acute normal tissue reactions in head-and-neck cancer patients treated with IMRT: influence of dose and association with genetic polymorphisms in DNA DSB repair genes. Int. J. Radiat. Oncol. Biol. Phys. 73, 1187-1195 (2009).
37. Ogden GR: Alcohol and oral cancer. Alcohol 35, 169-173 (2005). (Pubitemid 41079920)
38. Warnakulasuriya S, Sutherland G, Scully C: Tobacco, oral cancer, and treatment of dependence. Oral Oncol. 41, 244-260 (2005). (Pubitemid 40311753)
39. Gupta PC, Ray CS: Smokeless tobacco and health in India and South Asia. Respirology 8, 419-431 (2003). (Pubitemid 38009636)
40. Nair U, Bartsch H, Nair J: Alert for an epidemic of oral cancer due to use of the betel quid substitutes gutkha and pan masala: a review of agents and causative mechanisms. Mutagenesis 19, 251-262 (2004). (Pubitemid 39028948)
41. Bau DT, Tseng HC, Wang CH et al.: Oral cancer and genetic polymorphism of DNA double strand break gene Ku70 in Taiwan. Oral Oncol. 44, 1047-1051 (2008).
42. Hsu CF, Tseng HC, Chiu CF et al.: Association between DNA double strand break gene Ku80 polymorphisms and oral cancer susceptibility. Oral Oncol. 45, 789-793 (2009).
43. Chiu CF, Tsai MH, Tseng HC et al.: A novel single nucleotide polymorphism in XRCC4 gene is associated with oral cancer susceptibility in Taiwanese patients. Oral Oncol. 44, 898-902 (2008).
44. Tseng HC, Tsai MH, Chiu CF et al.: Association of XRCC4 codon 247 polymorphism with oral cancer susceptibility in Taiwan. Anticancer Res. 28, 1687-1691 (2008).
45. Yang H, Lippman SM, Huang M: Genetic polymorphisms in double-strand break DNA repair genes associated with risk of oral premalignant lesions. Eur. J. Cancer 44, 1603-1611 (2008).
46. Sherman SI: Thyroid carcinoma. Lancet 361, 501-511 (2003). (Pubitemid 36173719)
47. Kilfoy BA, Zheng T, Holford TR et al.: International patterns and trends in thyroid cancer incidence, 1973-2002. Cancer Causes Control 20, 525-531 (2009).
48. Cramer JD, Fu P, Harth KC, Margevicius S, Wilhelm SM: Analysis of the rising incidence of thyroid cancer using the Surveillance, Epidemiology and End Results National Cancer Data Registry. Surgery 148, 1147-1153 (2010).
49. Kondo T, Ezzat S, Asa SL: Pathogenetic mechanisms in thyroid follicular-cell neoplasia. Nat. Rev. Cancer 6, 292-306 (2006).
50. Silva SN, Gil OM, Oliveira VC et al.: Association of polymorphisms in ERCC2 gene with non-familial thyroid cancer risk. Cancer Epidemiol. Biomarkers Prev. 14, 2407-2412 (2005). (Pubitemid 41437844)
51. Henderson BE, Feigelson HS: Hormonal carcinogenesis. Carcinogenesis 21, 427-433 (2000). (Pubitemid 30137927)
52. Gomes BC, Silva SN, Azevedo AP et al.: The role of common variants of non-homologous end-joining repair genes XRCC4, LIG4 and Ku80 in thyroid cancer risk. Oncol. Rep. 24, 1079-1085 (2010).
53. Ando N, Ozawa S, Kitagawa Y, Shinozawa Y, Kitajima M: Improvement in the results of surgical treatment of advanced squamous esophageal carcinoma during 15 consecutive years. Ann. Surg. 232, 225-232 (2000). (Pubitemid 30616724)
54. Zhang H, Chen Z, Cheng J et al.: The high incidence of esophageal cancer in parts of China may result primarily from genetic rather than environmental factors. Dis. Esophagus 23, 392-397 (2010).
55. International Agency for Research on Cancer: IARC monographs on the evaluation of carcinogenic risks to humans. In: Alcohol Drinking. IARC Press, Lyon, France (1988).
56. International Agency for Research on Cancer: International Agency for Research on Cancer monograph 83: Tobacco Smoke and Involuntary Smoking. IARC Press, Lyon, France (2004).
57. Lee CH, Lee JM, Wu DC et al.: Independent and combined effects of alcohol intake, tobacco smoking and betel quid chewing on the risk of esophageal cancer in Taiwan. Int. J. Cancer 113, 475-482 (2005).
58. International Agency for Research on Cancer: International Agency for Research on Cancer Monographs on the Evaluation of Carcinogenic Risks to Human: Tobacco Smoking. IARC Press, Lyon, France (1986).
59. Dong XJ, Wang N, Guo W, Zhou RM, Zhang XJ, Li Y: [Correlations of XRCC5 polymorphisms to genetic susceptibility to esophageal squamous cell carcinoma and gastric cardiac adenocarcinoma in a high incidence region]. Ai Zheng 26, 280-284 (2007).
60. Parkin DM, Bray F, Ferlay J, Pisani P: Global cancer statistics, 2002. CA Cancer J. Clin. 55, 74-108 (2005). (Pubitemid 40372904)
61. Jemal A, Siegel R, Ward E, Hao Y, Xu J, Thun MJ: Cancer statistics, 2009. CA Cancer J. Clin. 59, 225-249 (2009).
62. Jackson C, Cunningham D, Oliveira J: Gastric cancer: ESMO clinical recommendations for diagnosis, treatment and follow-up. Ann. Oncol. 20(Suppl. 4), 34-36 (2009).
63. Gellad ZF, Provenzale D: Colorectal cancer: national and international perspective on the burden of disease and public health impact. Gastroenterology 138, 2177-2190 (2010).
64. Doll R, Peto R: The causes of cancer: quantitative estimates of avoidable risks of cancer in the United States today. J. Natl Cancer Inst. 66, 1191-1308 (1981). (Pubitemid 11063920)
65. Thomas HJ: Familial colorectal cancer. BMJ 307, 277-278 (1993). (Pubitemid 23220839)
66. Giovannucci E, Colditz GA, Stampfer MJ et al.: A prospective study of cigarette smoking and risk of colorectal adenoma and colorectal cancer in U.S. women. J. Natl Cancer Inst. 86, 192-199 (1994). (Pubitemid 24042260)
67. Heineman EF, Zahm SH, McLaughlin JK, Vaught JB: Increased risk of colorectal cancer among smokers: results of a 26?-year follow-up of US veterans and a review. Int. J. Cancer 59, 728-738 (1994).
68. Pryor WA, Hales BJ, Premovic PI, Church DF: The radicals in cigarette tar: their nature and suggested physiological implications. Science 220, 425-427 (1983). (Pubitemid 13163438)
69. Yang MD, Hsu YM, Kuo YS et al.: Significant association of Ku80 single nucleotide polymorphisms with colorectal cancer susceptibility in central Taiwan. Anticancer Res. 29, 2239-2242 (2009).
70. Jemal A, Siegel R, Ward E, Murray T, Xu J, Thun MJ: Cancer statistics, 2007. CA Cancer J. Clin. 57, 43-66 (2007). (Pubitemid 46148091)
71. Sanchez-Cespedes M: Lung cancer biology: a genetic and genomic perspective. Clin. Transl. Oncol. 11, 263-269 (2009).
72. Shields PG: Molecular epidemiology of smoking and lung cancer. Oncogene 21, 6870-6876 (2002). (Pubitemid 35221933)
73. Shields PG, Harris CC: Cancer risk and low-penetrance susceptibility genes in gene-environment interactions. J. Clin. Oncol. 18, 2309-2315 (2000). (Pubitemid 30350224)
74. Tseng RC, Chang JW, Hsien FJ et al.: Genomewide loss of heterozygosity and its clinical associations in non small cell lung cancer. Int. J. Cancer 117, 241-247 (2005).
75. Tseng RC, Hsieh FJ, Hsu HS, Wang YC: Minimal deletion regions in lung squamous cell carcinoma: association with abnormality of the DNA double-strand break repair genes and their applications on gene identification and prognostic biomarkers. Lung Cancer 59, 332-339 (2008).
76. Tseng RC, Hsieh FJ, Shih CM, Hsu HS, Chen CY, Wang YC: Lung cancer susceptibility and prognosis associated with polymorphisms in the nonhomologous end-joining pathway genes: a multiple genotype-phenotype study. Cancer 115, 2939-2948 (2009).
77. Agurs-Collins T, Dunn BK, Browne D, Johnson KA, Lubet R: Epidemiology of health disparities in relation to the biology of estrogen receptor-negative breast cancer. Semin. Oncol. 37, 384-401 (2010).
78. Coughlin SS, Ekwueme DU: Breast cancer as a global health concern. Cancer Epidemiol. 33, 315-318 (2009).
79. Freres P, Collignon J, Gennigens C et al.: 'Triple negative' breast cancer. Rev. Med. Liege 65, 120-126 (2010).
80. Goode EL, Dunning AM, Kuschel B et al.: Effect of germ-line genetic variation on breast cancer survival in a population-based study. Cancer Res. 62, 3052-3057 (2002). (Pubitemid 34602394)
81. Kuschel B, Auranen A, McBride S et al.: Variants in DNA double-strand break repair genes and breast cancer susceptibility. Hum. Mol. Genet. 11, 1399-1407 (2002).
82. Willems P, De Ruyck K, Van den Broecke R et al.: A polymorphism in the promoter region of Ku70/XRCC6, associated with breast cancer risk and oestrogen exposure. J. Cancer Res. Clin. Oncol. 135, 1159-1168 (2009).
83. McPherson K, Steel CM, Dixon JM: ABC of breast diseases. Breast cancer-epidemiology, risk factors, and genetics. BMJ 321, 624-628 (2000).
84. Lee KM, Choi JY, Kang C et al.: Genetic polymorphisms of selected DNA repair genes, estrogen and progesterone receptor status, and breast cancer risk. Clin. Cancer Res. 11, 4620-4626 (2005). (Pubitemid 40825653)
85. Cheng SH, Tsou MH, Liu MC et al.: Unique features of breast cancer in Taiwan. Breast Cancer Res. Treat. 63, 213-223 (2000).
86. Kuo WH, Yen AM, Lee PH et al.: Cumulative survival in early-onset unilateral and bilateral breast cancer: an analysis of 1907 Taiwanese women. Br. J. Cancer 100, 563-570 (2009).
87. Pharoah PD, Antoniou A, Bobrow M, Zimmern RL, Easton DF, Ponder BA: Polygenic susceptibility to breast cancer and implications for prevention. Nat. Genet. 31, 33-36 (2002)
88. Wang HC, Liu CS, Chiu CF et al.: Significant association of DNA repair gene Ku80 genotypes with breast cancer susceptibility in Taiwan. Anticancer Res. 29, 5251-5254 (2009).
89. Bau DT, Fu YP, Chen ST et al.: Breast cancer risk and the DNA double-strand break end-joining capacity of nonhomologous end-joining genes are affected by BRCA1. Cancer Res. 64, 5013-5019 (2004).
90. Lipworth L, Tarone RE, McLaughlin JK: The epidemiology of renal cell carcinoma. J. Urol. 176, 2353-2358 (2006). (Pubitemid 44665976)
91. Hunt JD, van der Hel OL, McMillan GP, Boffetta P, Brennan P: Renal cell carcinoma in relation to cigarette smoking: meta-ana-lysis of 24 studies. Int. J. Cancer 114, 101-108 (2005). (Pubitemid 40194314)
92. Hirata H, Hinoda Y, Matsuyama H et al.: Polymorphisms of DNA repair genes are associated with renal cell carcinoma. Biochem. Biophys. Res. Commun. 342, 1058-1062 (2006).
93. Margulis V, Lin J, Yang H, Wang W, Wood CG, Wu X: Genetic susceptibility to renal cell carcinoma: the role of DNA double-strand break repair pathway. Cancer Epidemiol. Biomarkers Prev. 17, 2366-2373 (2008).
94. Parkin DM, Bray F, Ferlay J, Pisani P: Estimating the world cancer burden: Globocan 2000. Int. J. Cancer 94, 153-156 (2001). (Pubitemid 32911406)
95. International Agency for Research on Cancer: Cancer Incidence. IARC Cancer Base No. 5: Mortality and Prevalence Worldwide. Version 1.0. IARC Press, Lyon, France (2001).
96. Jemal A, Murray T, Ward E et al.: Cancer statistics, 2005. CA Cancer J. Clin. 55, 10-30 (2005). (Pubitemid 40310185)
97. Jemal A, Ward E, Hao Y, Thun M: Trends in the leading causes of death in the United States, 1970-2002. JAMA 294, 1255-1259 (2005). (Pubitemid 41352114)
98. International Agency for Research on Cancer. IARC Monographs on the Evaluation of the Carcinogenic Risk of Chemicals to Humans: Tobacco Smoking. IARC Press, Lyon, France (1985).
99. Bruemmer B, White E, Vaughan TL, Cheney CL: Nutrient intake in relation to bladder cancer among middle-aged men and women. Am. J. Epidemiol. 144, 485-495 (1996). (Pubitemid 26296132)
100. Bruemmer B, White E, Vaughan TL, Cheney CL: Fluid intake and the incidence of bladder cancer among middle-aged men and women in a three-county area of western Washington. Nutr. Cancer 29, 163-168 (1997). (Pubitemid 28009839)
101. Gago-Dominguez M, Castelao JE, Yuan JM, Yu MC, Ross RK: Use of permanent hair dyes and bladder-cancer risk. Int. J. Cancer 91, 575-579 (2001). (Pubitemid 32115116)
102. Sun CL, Yuan JM, Arakawa K, Low SH, Lee HP, Yu MC: Dietary soy and increased risk of bladder cancer: the Singapore Chinese Health Study. Cancer Epidemiol. Biomarkers Prev. 11, 1674-1677 (2002). (Pubitemid 36020023)
103. Zeegers MP, Tan FE, Verhagen AP, Weijenberg MP, van den Brandt PA: Elevated risk of cancer of the urinary tract for alcohol drinkers: a meta-analysis. Cancer Causes Control 10, 445-451 (1999). (Pubitemid 29454323)
104. Stronati L, Gensabella G, Lamberti C et al.: Expression and DNA binding activity of the Ku heterodimer in bladder carcinoma. Cancer 92, 2484-2492 (2001). (Pubitemid 33029095)
105. Li GC, Ouyang H, Li X et al.: Ku70: a candidate tumor suppressor gene for murine T cell lymphoma. Mol. Cell 2, 1-8 (1998). (Pubitemid 128378961)
106. Wang S, Wang M, Yin S et al.: A novel variable number of tandem repeats (VNTR) polymorphism containing Sp1 binding elements in the promoter of XRCC5 is a risk factor for human bladder cancer. Mutat. Res. 638, 26-36 (2008).
107. Wang SY, Peng L, Li CP et al.: Genetic variants of the XRCC7 gene involved in DNA repair and risk of human bladder cancer. Int. J. Urol. 15, 534-539 (2008). (Pubitemid 351713194)
108. Johansson SL, Cohen SM: Epidemiology and etiology of bladder cancer. Semin. Surg. Oncol. 13, 291-298 (1997). (Pubitemid 27332851)
109. Dolin PJ: An epidemiological review of tobacco use and bladder cancer. J. Smoking Related Dis. 2, 129-143 (1991).
110. Lijinsky W, Thomas BJ, Kovatch RM: Systemic and local carcinogenesis by directly acting N-nitroso compounds given to rats by intravesicular administration. Carcinogenesis 13, 1101-1105 (1992).
111. Michiels S, Laplanche A, Boulet T et al.: Genetic polymorphisms in 85 DNA repair genes and bladder cancer risk. Carcinogenesis 30, 763-768 (2009).
112. Wu X, Gu J, Grossman HB et al.: Bladder cancer predisposition: a multigenic approach to DNA-repair and cell-cycle-control genes. Am. J. Hum. Genet. 78, 464-479 (2006). (Pubitemid 43291228)
113. Chang CH, Chiu CF, Liang SY et al.: Significant association of Ku80 single nucleotide polymorphisms with bladder cancer susceptibility in Taiwan. Anticancer Res. 29, 1275-1279 (2009).
114. Gronberg H: Prostate cancer epidemiology. Lancet 361, 859-864 (2003). (Pubitemid 36331852)
115. Hsing AW, Chokkalingam AP: Prostate cancer epidemiology. Front. Biosci. 11, 1388-1413 (2006). (Pubitemid 43253429)
116. Akakura K, Tsujii H, Morita S et al.: Phase I/II clinical trials of carbon ion therapy for prostate cancer. Prostate 58, 252-258 (2004). (Pubitemid 38168922)
117. Ishikawa H, Tsuji H, Kamada T et al.: Risk factors of late rectal bleeding after carbon ion therapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 66, 1084-1091 (2006). (Pubitemid 44633528)
118. Tsuji H, Yanagi T, Ishikawa H et al.: Hypofractionated radiotherapy with carbon ion beams for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 63, 1153-1160 (2005). (Pubitemid 41505295)
119. Suga T, Ishikawa A, Kohda M et al.: Haplotype-based analysis of genes associated with risk of adverse skin reactions after radiotherapy in breast cancer patients. Int. J. Radiat. Oncol. Biol. Phys. 69, 685-693 (2007). (Pubitemid 47418413)
120. Suga T, Iwakawa M, Tsuji H et al.: Influence of multiple genetic polymorphisms on genitourinary morbidity after carbon ion radiotherapy for prostate cancer. Int. J. Radiat. Oncol. Biol. Phys. 72, 808-813 (2008).
121. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC: Multiple myeloma. Lancet 374, 324-339 (2009).
122. Azais I, Brault R, Debiais F: New treatments for myeloma. Joint Bone Spine 77, 20-26 (2010).
123. Hayden PJ, Tewari P, Morris DW et al.: Variation in DNA repair genes XRCC3, XRCC4, XRCC5 and susceptibility to myeloma. Hum. Mol. Genet. 16, 3117-3127 (2007). (Pubitemid 350131330)
124. Johnson DC, Corthals S, Ramos C et al.: Genetic associations with thalidomide mediated venous thrombotic events in myeloma identified using targeted genotyping. Blood 112, 4924-4934 (2008).
125. Tewari P, Kenny E, Staines A, Chanock S, Browne P, Lawler M: Genetic variants in XRRC5 may predict development of venous thrombotic events in myeloma patients on thalidomide. Blood 113, 5691-5692 (2009).
126. Detorakis ET, Drakonaki EE, Spandidos DA: Molecular genetic alterations and viral presence in ophthalmic pterygium. Int. J. Mol. Med. 6, 35-41 (2000).
127. Tsai YY, Bau DT, Chiang CC, Cheng YW, Tseng SH, Tsai FJ: Pterygium and genetic polymorphism of DNA double strand break repair gene Ku70. Mol. Vis. 13, 1436-1440 (2007).
128. Evans WE, McLeod HL: Pharmacogenomics -drug disposition, drug targets, and side effects. N. Engl. J. Med. 348, 538-549 (2003).
129. Kawai Y, Kikuchi T, Mitani Y et al.: Sensitive detection of EGFR mutations using a competitive probe to suppress background in the SMart Amplification Process. Biologicals 36, 234-238 (2008).
130. Haselden JN, Nicholls AW: Personalized medicine progresses. Nat. Med. 12, 510-511 (2006).
131. Wu CN, Liang SY, Tsai CW, Bau DT: The role of XRCC4 in carcinogenesis and anticancer drug discovery. Recent Pat. Anticancer Drug Discov. 3, 209-219 (2008).
132. Dolan ME, Moschel RC, Pegg AE: Depletion of mammalian O6-alkylguanine-DNA alkyltransferase activity by O6-benzylguanine provides a means to evaluate the role of this protein in protection against carcinogenic and therapeutic alkylating agents. Proc. Natl Acad. Sci. USA 87, 5368-5372 (1990).
133. Kaina B, Muhlhausen U, Piee-Staffa A et al.: Inhibition of O6-methylguanine-DNA methyltransferase by glucose-conjugated inhibitors: comparison with nonconjugated inhibitors and effect on fotemustine and temozolomide-induced cell death. J. Pharmacol. Exp. Ther. 311, 585-593 (2004). (Pubitemid 39391543)
134. Andreassen CN, Alsner J, Overgaard M, Overgaard J: Prediction of normal tissue radiosensitivity from polymorphisms in candidate genes. Radiother. Oncol. 69, 127-135 (2003). (Pubitemid 37485871)
135. Isla D, Sarries C, Rosell R et al.: Single nucleotide polymorphisms and outcome in docetaxel-cisplatin-treated advanced non-small-cell lung cancer. Ann. Oncol. 15, 1194-1203 (2004). (Pubitemid 39199306)
136. Ryu JS, Hong YC, Han HS et al.: Association between polymorphisms of ERCC1 and XPD and survival in non-small-cell lung cancer patients treated with cisplatin combination chemotherapy. Lung Cancer 44, 311-316 (2004).
137. Futami K, Takagi M, Shimamoto A, Sugimoto M, Furuichi Y: Increased chemotherapeutic activity of camptothecin in cancer cells by siRNA-induced silencing of WRN helicase. Biol. Pharm. Bull. 30, 1958-1961 (2007). (Pubitemid 47607770)